Lumula

Confirm delete?

Lumula

Zoom

Cat No: 16685

Biochemicals - Lipids

Lumula is a hybrid eicosanoid analog that incorporates the docosanoid and prostamide features of unoprostone (Item No. 16680) and bimatoprost (17-phenyl trinor Prostaglandin F2α ethyl amide; Item No. 16820), respectively, prostaglandin analogs that la...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

N-ethyl-9?,11?-dihydroxy-15-oxo-20a,20b-dihomoprost-5-en-1-amide

Correlated keywords:

prostaglandins PGF2alpha PGF2.alpha. analogs hypotensive hypotension intraocular pressure ophthalmological eyes ophthalmology iop glaucoma prostamide docosanoid docosaprostamide

Product Overview:
Lumula is a hybrid eicosanoid analog that incorporates the docosanoid and prostamide features of unoprostone (Item No. 16680) and bimatoprost (17-phenyl trinor Prostaglandin F2α ethyl amide; Item No. 16820), respectively, prostaglandin analogs that lack potency at the prostanoid FP receptor.{55268,19618,9658} Based on classical structure-activity relationships that have been established for prostanoid receptors, lumula is predicted to have low activity at these receptors.{8322} The N-ethyl amide prodrug moiety it inherits from bimatoprost is slow to hydrolyze and the lower side chain modifications inherited from unoprostone interfere with FP receptor binding.{9311,2058} Lumula is intended for use as a negative control for testing mechanisms of unoprostone and bimatoprost activity.

Size	100 µg
Shipping	dry ice
CAS Number	511229-72-4
Molecular Formula	C₂₄H₄₃NO₄
SMILES	O[C@@H]1[C@H](C/C=C\CCCC(N([H])CC)=O)[C@@H](CCC(CCCCCCC)=O)[C@H](O)C1
Molecular Weight	409,6
Formulation	A solution in methyl acetate
Purity	≥98%
Custom Code	2937.50
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.